Article
Author(s):
Gevokizumab, an IL-1 beta-modulating antibody from XOMA Corp., has received FDA orphan drug designation for the treatment of several types of non-infectious uveitis.
Berkeley, CA-Gevokizumab, an interleukin-1 beta (IL-1 beta)-modulating antibody from XOMA Corp., has been granted orphan drug designation by the FDA for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis.
Gevokizumab is a monoclonal antibody with allosteric modulating properties and the potential to treat patients who have a wide variety of inflammatory and other diseases. Gevokizumab binds strongly to IL-1 beta, a pro-inflammatory cytokine that has been shown to be involved in Behcet's and other forms of non-infectious uveitis, cardiovascular disease, and other auto-inflammatory diseases. In binding to IL-1 beta, gevokizumab inhibits the activation of the IL-1 receptor, thereby modulating the cellular signaling events that produce inflammation.
For more articles in this issue of Ophthalmology Times eReport, click here.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.